{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2(2)"],"submitter":["Alvarez-Buylla A"],"funding":["Merck Sharp and Dohme"],"pubmed_abstract":["<h4>Objectives</h4>To evaluate the <i>in vitro</i> activity of ceftolozane/tazobactam and other commonly used antipseudomonal antibiotics against geographically spread <i>Pseudomonas aeruginosa</i> isolates in the UK using disc susceptibility testing.<h4>Methods</h4>The <i>in vitro</i> activity of ceftolozane/tazobactam and nine other commonly used antipseudomonal antibiotics was evaluated. Isolates were collected between January 2015 and April 2018. Susceptibility results were interpreted using EUCAST 2018 criteria.<h4>Results</h4>Overall, 1326 clinical isolates from 14 centres in the UK were tested. The majority of the isolates were collected from non-cystic fibrosis (non-CF) patients (<i>n </i>=<i> </i>1123, 85.0%). In addition, 199 cystic fibrosis (CF) isolates were collected from 10 c"],"journal":["JAC-antimicrobial resistance"],"pagination":["dlaa024"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8209992"],"repository":["biostudies-literature"],"pubmed_title":["Multicentre study of the <i>in vitro</i> activity of ceftolozane/tazobactam and other commonly used antibiotics against <i>Pseudomonas aeruginosa</i> isolates from patients in the UK."],"pmcid":["PMC8209992"],"pubmed_authors":["INVICTUS study group","Alvarez-Buylla A","Allen M","Bennett S","Betts D","Monahan I","Planche T"],"additional_accession":[]},"is_claimable":false,"name":"Multicentre study of the <i>in vitro</i> activity of ceftolozane/tazobactam and other commonly used antibiotics against <i>Pseudomonas aeruginosa</i> isolates from patients in the UK.","description":"<h4>Objectives</h4>To evaluate the <i>in vitro</i> activity of ceftolozane/tazobactam and other commonly used antipseudomonal antibiotics against geographically spread <i>Pseudomonas aeruginosa</i> isolates in the UK using disc susceptibility testing.<h4>Methods</h4>The <i>in vitro</i> activity of ceftolozane/tazobactam and nine other commonly used antipseudomonal antibiotics was evaluated. Isolates were collected between January 2015 and April 2018. Susceptibility results were interpreted using EUCAST 2018 criteria.<h4>Results</h4>Overall, 1326 clinical isolates from 14 centres in the UK were tested. The majority of the isolates were collected from non-cystic fibrosis (non-CF) patients (<i>n </i>=<i> </i>1123, 85.0%). In addition, 199 cystic fibrosis (CF) isolates were collected from 10 c","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2025-04-18T19:15:17.015Z","creation":"2022-02-10T18:01:12.236Z"},"accession":"S-EPMC8209992","cross_references":{"pubmed":["34222988"],"doi":["10.1093/jacamr/dlaa024"]}}